Author:
Birmingham Bruce K.,Bujac Sarah R.,Elsby Robert,Azumaya Connie T.,Zalikowski Julie,Chen Yusong,Kim Kenneth,Ambrose Helen J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference30 articles.
1. Warwick MJ, Dane AL, Raza A, Schneck DW (2000) Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 151:39
2. Martin PD, Mitchell PD, Schneck DW (2002) Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 54:472–477
3. Sekino H, Onishi T (2005) Phase I study of ZD4522 (rosuvastatin), a new HMG-CoA reductase inhibitor—evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J Clin Ther Med 21:187–203
4. Tzeng T-B, Schneck DW, Birmingham B, Mitchell PD, Zhang H, Martin PD, Kung L-P (2008) Population pharmacokinetics of rosuvastatin: implications of renal impairment, race and dyslipidaemia. Curr Med Res Opin 24:2575–2585
5. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330–341
Cited by
118 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献